The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The FDA is considering removing single drug long acting Beta Agonist from the market. They believe they have the potential to cause harm. They are considering removing component therapy drugs that contain long acting Beta agonist like Symbicort and Advair also. This would lead to a major problem for...
Some information of note, the current FDA briefing document (http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-00-index.htm) is a publication entirely created by GSK, Novartis, and AstraZeneca and not an independently created FDA review. It merely is a summary of trials data already...
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary...
I agree with the premise of the article -- that diuretics may be underutilized as a cheap way to get the benefits of antihypertensives. However, more than 40% of my HTN patients are on diuretics, and I think the data presented in the NY Times article may be flawed. Here's why:
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
In a recent article it is noted that for users of Ipatropium bromide there was an increase in all death and cardiac death in the group studied. Theoretically at doses normally used there is not much of a corresponding mechanistic risk. Therefore at this time additional study must be done...